

**Date: 29th July, 2024**

To

BSE Limited

Listing Department,
Phiroze Jeejeebhoy Towers,
Dalal Street - Fort,
Mumbai — 400 001.

Ref.: BSE Scrip Code - 539730**Subject: Outcome of Board Meeting**

Dear Sir / Madam,

Pursuant to Regulation 30 and 33 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 we wish to inform you that the Board of Directors of the Company at its meeting held today i.e. Monday, July 29, 2024 has inter-alia, considered, adopted and approved following items of business:

1. In compliance to Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Un-Audited Financial Results of the Company for the Quarter Ended 30th June, 2024 along with the Limited Review Report as issued by M/s. R.H. Nisar & Co, Statutory Auditors of the Company; copies of which are attached hereunder;

In furtherance to the intimation filed by the Company dated June 27, 2024; the trading window for trading in securities of the Company by insiders closed on July 01, 2024 till the end of 48 hours after the declaration of outcome of Board Meeting.

The Board Meeting commenced at 04:00 p.m. and concluded at 07:15 p.m.

Kindly oblige and take the same on your Records.

Thanking you,**For Fredun Pharmaceuticals Limited****Jinkal Shah****(Jinkal Soni)****Company Secretary and Compliance Officer****Membership No.: A40722**

R.H.Nisar & Co.
Chartered Accountant

4, Vrindavan Building, Aarey Road, Goregaon (E), Mumbai – 400 063
Tel no: 2686 9939, 2686 9940

Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Fredun Pharmaceuticals Limited,

1. We have reviewed the accompanying statement of standalone unaudited financial results ('the Statement') of Fredun Pharmaceuticals Limited ('the Company') for the quarter ended 30 June 2024, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').
2. The Statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.

R.H.Nisar & Co.
Chartered Accountant

4, Vrindavan Building, Aarey Road, Goregaon (E), Mumbai – 400 063
Tel no: 2686 9939, 2686 9940

5. The Statement regarding the Standalone figures for the quarter ended 31 March 2024, which are balancing figures between audited figures in respect of full year and the published unaudited year-to-date figures up to third quarter of the previous financial year, which were subject to a limited review by us.

FOR R H NISAR & CO.
CHARTERED ACCOUNTANTS
FIRM'S REGISTRATION NUMBER: 120895W

Digitally signed by
RAKESH HIRJI
NISAR
HIRJI NISAR Date: 2024.07.29
17:56:08 +05'30'

RAKESH NISAR
PROPRIETOR
MEMBERSHIP NO. 103659
UDIN: 24103659BKCQFZ8241

PLACE: MUMBAI
DATE: 29.07.2024



FREDUN PHARMACEUTICALS LIMITED

Compassionate Healthcare



CIN No : L24239MH1987PLC043662

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30.06.2024

Rs. In Lakhs

PARTICULARS	Quarter Ended		Year Ended	
	UnAudited	Audited	UnAudited	Audited
	30.06.24	31.03.24	30.06.23	31.03.24
1 Income from Operations				
Net Sales /IncomeFrom Operation (Net of GST)	7753.58	11721.42	6122.70	34657.69
2 Other Operating Income	127.50	81.88	81.85	249.49
3 Total income from operatoins (net)	7881.08	11803.30	6204.55	34907.18
4 Expenses				
a) Cost of Material Consumed	5750.67	9156.61	3443.90	28241.83
b) Cost of Material Consumed for R & D	37.68	25.02	28.12	134.19
c) Other R & D Expenses	0.00	0.00	0.00	0.00
d) Changes in inventories of finished goods, work-in-progress and stock in trade	(32.68)	(189.65)	1077.88	(2243.65)
e) Manufacturing & Service Cost	327.68	411.73	221.14	1361.65
f) Finance Costs	391.24	437.17	261.23	1365.01
g) Employess benefits expenses	309.94	390.03	269.43	1249.98
h) Depreciation and amortisation expenses	104.72	95.63	91.50	379.59
i) Other Expenses	439.93	892.91	403.34	2273.39
Total expenses	7329.18	11219.45	5796.54	32761.99
5 Profit/(Loss) from ordinary activities before exceptional items & tax (3-4)	551.90	583.85	408.01	2145.19
6 Exceptional items / Prior Period Item	0.00	0.00	0.00	0.00
7 Profit/(Loss) from ordinary activities before tax (5-6)	551.90	583.85	408.01	2145.19
8 Tax Expenses	138.91	77.61	167.84	582.85
9 Profit/(Loss) from continuing operations	412.99	506.24	240.17	1562.34
10 Profit/(Loss) from discontinued operations	0.00	0.00	0.00	0.00
11 Tax Expense of discontinued operations	0.00	0.00	0.00	0.00
12 Profit/(Loss) from discontinued operations after tax	0.00	0.00	0.00	0.00
13 Profit/ (Loss) for the period	412.99	506.24	240.17	1562.34
14 Other comprehensive Income				
A (i) Items that will not be re-classified to profit/ loss classified to profit/ loss	0.00	0.00	0.00	0.00
B (i) Re measurement of post - employment benefit obligations	0.00	7.04	0.00	7.04
C (i) Items that will be re-classified to profit / loss profit/ loss	0.00	0.00	0.00	0.00
Total Comprehensive Income for the year	412.99	513.28	240.17	1569.38

Registered Office: Urmi Estate, 11th Floor, Ganpatrao Kadam Marg, Lower Parel (W), Mumbai - 400013.

Phone No.: 91-22- 4031 8111 Fax: 91-22-4031 8133

Factory: 14,15,16, Zorabian Industrial Complex, Vevoor, Palghar (E), Dist: Palghar - 401 404.

Phone No.: +917045957828, +917045957829, +917045957830, +917045956857

E-Mail: business@fredungroup.com Web: www.fredungroup.com

FREDUN PHARMACEUTICALS LIMITED

Compassionate Healthcare



CIN No : L24239MH1987PLC043662

	PARTICULARS	Quarter Ended			Year Ended
		UnAudited	Audited	UnAudited	Audited
		30.06.24	31.03.24	30.06.23	31.03.24
15	Paid up Equity Share Capital (Face Value of Rs-10/- each)	469.92	469.92	458.01	469.92
16	Reserves excluding Revaluation Reserves	0.00	0.00	0.00	11677.20
17	Earning per Share (EPS) (before & after extra ordinary items)				
	- Basic/ Diluted Earning Per Share (Rs.)	8.79	10.77	5.24	33.32
A	1) Public Shareholding				
	Number of shares	2388777	2388777	2272745	2388777
	Percentage of shareholding	50.83%	50.83%	49.62%	50.83%
	2) Promoters and promotor group shareholding				
	a) Pledged/Encumbered				
	- Number of shares	-	-	-	-
	- Percentage of shares (as a % of total shareholding of Promoters and Prompter Group)	-	-	-	-
	- Percentage of shares (as a % of total share capital of the Company)	-	-	-	-
	b) Non-encumbered				
	- Number of shares	2310385	2310385	2307377	2310385
	- Percentage of shares (as a % of total shareholding of Promoters and Prompter Group)	100%	100%	100%	100%
	- Percentage of shares (as a % of total share capital of the Company)	49.17%	49.17%	50.38%	49.17%

Notes

- The above unaudited financial results which are published in accordance with Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on July 29, 2024. These unaudited financial results have been prepared in accordance with recognition and measurement principles of Indian Accounting Standards ("Ind AS") as prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and the other accounting principles generally accepted in India.
- The above unaudited financial results for the quarter ended June 30, 2024 are prepared in compliance with the Ind AS which have been subjected to a limited review by the statutory auditors of the Company. The statutory auditors, Rakesh Nisar & Co have issued limited review reports with unmodified conclusion on the standalone and consolidated unaudited financial results.
- As the Company's business activity falls within a single operating segment viz "Pharmaceutical and Healthcare", no segment information is disclosed.
- The figures for the quarter ended March 31, 2024 are the balancing figures between audited figures in respect of the full financial year and the published year to date unaudited figures upto the third quarter of the previous financial year.
- The figures for the earlier periods have been regrouped/ reclassified wherever necessary to make them comparable with those of the current period.
- The above results were reviewed and recommended by the Audit Committee, for approval by the Board, at its meeting held on 29th July 2024 and were approved and taken on record at the meeting of the Board of Directors of the company held on that date

PLACE: MUMBAI

DATE : 29th July 2024



FOR FREDUN PHARMACEUTICALS LIMITED

MANAGING DIRECTOR & CFO
FREDUN N. MEDHORA
DIN : 01745348

Registered Office: Urmi Estate, 11th Floor, Ganpatrao Kadam Marg, Lower Parel (W), Mumbai - 400013.

Phone No.: 91-22- 4031 8111 Fax: 91-22-4031 8133

Factory: 14,15,16, Zorabian Industrial Complex, Vevoor, Palghar (E), Dist: Palghar - 401 404.

Phone No.: +917045957828, +917045957829, +917045957830, +917045956857

E-Mail: business@fredungroup.com Web: www.fredungroup.com